Hunan Hansen Pharmaceutical Co Ltd

Hunan Hansen Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 4.58, indicating that it has sufficient current assets to cover its current liabilities. The company's liquidity FPT (free cash flow to total liabilities) is supported by a free cash flow of 226.58 million CNY and total liabilities of 312.15 million CNY, suggesting a healthy cash buffer. However, the company has a net cash position that is negative after subtracting total debt, which could pose a liquidity risk in the short term.

In terms of profitability, the company's return on equity (ROE) of 8.32% and return on assets (ROA) of 7.36% are both above the industry median for pharmaceutical companies, indicating strong returns relative to its equity and asset base. The gross profit margin of 77.35% (calculated as gross profit of 803.03 million CNY divided by revenue of 1,038.76 million CNY) is also robust, suggesting efficient cost management and pricing power.

The company's revenue is concentrated in a single geographic market, primarily China, with no disclosed international operations. This concentration increases exposure to domestic economic and regulatory shifts. The company does not report segment-level revenue, so it is unclear whether its product lines or therapeutic areas are balanced or if it is over-reliant on a specific product or market.

Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant changes in revenue or earnings expected in the next fiscal year. The company's capital expenditure of -11.10 million CNY suggests a reduction in investment in new projects or facilities, which may indicate a focus on cost control or a shift in strategic priorities. The company's diluted earnings per share (EPS) are not expected to change significantly, as the number of shares outstanding remains unchanged between basic and diluted shares.

The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The low dilution risk is supported by the absence of recent share issuance or ATM/shelf registration activity. However, the company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations or invest in growth without external financing. The company's debt-to-equity ratio of 0.03 is low, indicating a conservative capital structure with minimal leverage.

Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest financial report, as of the most recent period, shows a stable operating cash flow of 245.38 million CNY, which supports its liquidity position. No significant regulatory or legal issues have been disclosed in the latest filings, and the company appears to be in compliance with applicable laws and regulations.

Hunan Hansen Pharmaceutical Co Ltd (002412.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with industry standards for sector-specific analysis. In terms of risk assessment, the company now carries a "low" dilution risk rating. This classification suggests that the likelihood of significant share count expansion or equity dilution is currently assessed as minimal, offering a degree of stability for existing shareholders regarding their ownership percentage. Conversely, the liquidity risk has been established at a "medium" level. This indicates that while the company is not facing immediate liquidity crises, there are moderate considerations regarding the ease of trading its shares or accessing liquid capital, a factor that investors typically monitor alongside dilution metrics. These updates represent the initial establishment of these specific risk and classification fields for Hun Hansen, moving from undefined states to defined ratings. The combination of low dilution risk and medium liquidity risk, set against a clear pharmaceutical sector classification, forms the baseline for evaluating the company's financial structure and market positioning.